Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type 2 diabetes. Adults without diabetes lost 15% to 20.9% of their body weight, depending on the dosage.

There is also an FDA box warning for thyroid C-cell tumors ... but the drug does not have FDA approval for this use. Zepbound is an injectable weight-loss drug for people who have obesity or ...

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's (LLY) tirzepatide, which is marketed for diabetes as Mounjaro and for weight loss as Zepbound.

In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...

Lilly’s weekly Zepbound is the frontrunner among obesity treatments on the market — helping patients lose an average of 20.2% of their body weight over a 72-week period. However, by comparison, ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.